Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
MWN-AI** Summary
Sutro Biopharma, Inc. (NASDAQ: STRO), a pioneering oncology firm focused on innovative antibody drug conjugates (ADCs), reported its full-year financial results for 2024 and outlined significant business updates. The company has undertaken a strategic portfolio review, which has led to a prioritization of its next-generation ADC programs. This initiative is envisioned to optimize resources and focus on delivering high-value products.
As of December 31, 2024, Sutro reported cash, cash equivalents, and marketable securities totaling $316.9 million, a decrease from $388.3 million reported in the prior quarter. Importantly, the company projects a cash runway extending into at least Q4 2026, which does not include anticipated milestones from existing collaborations. Revenue for the year stood at $62.0 million, significantly lower than the $153.7 million recorded in 2023, largely due to changes in collaboration dynamics with Astellas and Tasly.
Operating expenses rose to $300.5 million in 2024, compared to $243 million the previous year, driven primarily by increased research and development investments, which accounted for $252 million of the total expenses. Following the strategic review, Sutro expects to incur restructuring costs between $40 million and $45 million, which will contribute to long-term cost reductions and align with their refocused development goals.
Sutro will hold a conference call today at 2:00 p.m. PT to further discuss these developments, including upcoming clinical priorities and the reorganization of their management structure. The company's commitment to developing precisely designed cancer therapeutics remains strong as it seeks to enhance patient outcomes through its innovative pipeline.
MWN-AI** Analysis
Sutro Biopharma, Inc. (NASDAQ: STRO) recently reported its financial results for the full year 2024, highlighting significant shifts in its operational strategy. The company has initiated a strategic portfolio review aimed at focusing on its next-generation antibody-drug conjugate (ADC) programs, suggesting a commitment to innovation within its pipeline. Given the reduction in cash reserves from $388.3 million to $316.9 million since September 2024, investors should closely monitor the implications of this transition on Sutro's long-term viability and market performance.
Revenue plunged significantly to $62 million from $153.7 million in the previous year, primarily reflecting reduced collaboration revenues. This decline raises questions regarding the future viability of Sutro's business model and underscores the need for the company to cultivate new partnerships and revenue streams. The significant increase in operating expenses to $300.5 million—and the nearly doubling of its annual loss to $227.5 million—also highlights potential liquidity concerns, despite the extended cash runway into Q4 2026.
The announced management changes and restructuring expenditures estimated between $40 and $45 million may lead to cost efficiencies in clinical development. However, the effectiveness of these measures will largely hinge on successful execution and timely progress in drug development. The upcoming conference call will be crucial for delving deeper into how these changes could translate into improved financial health.
From a market perspective, investors may see potential in Sutro's focus on ADCs, particularly if successful trials emerge. Nonetheless, caution is warranted due to the uncertain short-term revenue prospects and the significant operational losses. Overall, a wait-and-see approach is advisable until there’s clearer visibility on the outcomes of the strategic pivot and overall pipeline progression.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition –
– Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations –
– Conference call today at 2:00 p.m. PT / 5:00 p.m. ET –
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2024 and recent business highlights. The Company also announced the completion of a strategic portfolio review resulting in the prioritization of its next-generation ADC pipeline. A conference call will be held today at 2:00 p.m. PT / 5:00 p.m. ET to discuss the pipeline reprioritization, team restructuring and next steps.
Full Year 2024 Financial Highlights
Cash, Cash Equivalents and Marketable Securities
As of December 31, 2024, Sutro had cash, cash equivalents and marketable securities of $316.9 million, as compared to $388.3 million as of September 30, 2024. Cash runway is expected into at least Q4 2026, excluding anticipated milestones from existing collaborations.
Revenue
Revenue was $62.0 million for the year ended December 31, 2024, as compared to $153.7 million for the year ended December 31, 2023, with the 2024 amount related principally to the Astellas collaboration and the Tasly agreement. Future collaboration and license revenue under existing agreements, and from any additional collaboration and license partners, will fluctuate as a result of the amount and timing of revenue recognition of upfront, milestones, and other agreement payments.
Operating Expenses
Total operating expenses for the year ended December 31, 2024 were $300.5 million, as compared to $243.0 million for year ended December 31, 2023. The year 2024 includes non-cash expenses for stock-based compensation of $24.7 million and depreciation and amortization of $7.2 million, as compared to $24.9 million and $6.8 million, respectively, in the year 2023. Total operating expenses for the year ended December 31, 2024 were comprised of research and development expenses of $252.0 million and general and administrative expenses of $48.5 million.
Restructuring Expenditures
Cash payments resulting from the strategic portfolio review and related restructuring are estimated to be $40 to $45 million. Cost reductions subsequently realized from the restructuring, combined with refocused clinical development priorities give the Company an expected cash runway into at least the fourth quarter of 2026, excluding anticipated milestones from existing collaborations.
Conference Call Details
The Company will host a conference call and webcast today at 2:00 p.m. PT/ 5:00 p.m. ET. The webcast information will also be available through the News & Events section of the Investors portion of the Company’s website at www.sutrobio.com . An archived replay will be available for at least 30 days after the event.
About Sutro Biopharma
Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF ® , provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media?@Sutrobio, or visit www.sutrobio.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, including enrollment and site activation; timing of announcements of clinical results, trial initiation, and regulatory filings; outcome of discussions with regulatory authorities; potential benefits of the Company’s product candidates and platform; potential business development and partnering transactions; potential market opportunities for the Company’s product candidates; the timing of exiting the manufacturing facility in San Carlos; the timing and receipt of anticipated future milestone payments; the Company’s expected cash runway; and the expected costs and cost reductions associated with the restructuring. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
| Sutro Biopharma, Inc. Selected Statements of Operations Financial Data (Unaudited) (In thousands, except share and per share amounts) | ||||||||||||
| For the year ended December 31 | ||||||||||||
| 2024 | 2023 | 2022 | ||||||||||
| Revenues | $ | 62,043 | $ | 153,731 | $ | 67,772 | ||||||
| Operating expenses | ||||||||||||
| Research and development | 252,043 | 180,425 | 137,171 | |||||||||
| General and administrative | 48,453 | 62,584 | 59,544 | |||||||||
| Total operating expenses | 300,496 | 243,009 | 196,715 | |||||||||
| Loss from operations | (238,453 | ) | (89,278 | ) | (128,943 | ) | ||||||
| Interest income | 18,643 | 14,510 | 3,455 | |||||||||
| Unrealized gain on equity securities | - | 9,917 | 12,130 | |||||||||
| Non-cash interest expense related to the sale of future royalties | (31,070 | ) | (12,570 | ) | - | |||||||
| Interest and other income (expense), net | 25,782 | (11,180 | ) | (3,346 | ) | |||||||
| Loss before provision for income taxes | (225,098 | ) | (88,601 | ) | (116,704 | ) | ||||||
| Provision for income taxes | 2,363 | 18,192 | 2,500 | |||||||||
| Net loss | $ | (227,461 | ) | $ | (106,793 | ) | $ | (119,204 | ) | |||
| Net loss per share, basic and diluted | $ | (2.96 | ) | $ | (1.78 | ) | $ | (2.35 | ) | |||
| Weighted-average shares used in computing basic and diluted net loss per share | 76,829,198 | 60,163,542 | 50,739,185 | |||||||||
| Sutro Biopharma, Inc. Selected Balance Sheets Financial Data (Unaudited) (In thousands) | ||||||||
| December 31, | ||||||||
| 2024 (1) | 2023 (2) | |||||||
| Assets | ||||||||
| Cash, cash equivalents and marketable securities | $ | 316,895 | $ | 333,681 | ||||
| Investment in equity securities | - | 41,937 | ||||||
| Accounts receivable | 8,616 | 36,078 | ||||||
| Property and equipment, net | 18,190 | 21,940 | ||||||
| Operating lease right-of-use assets | 17,677 | 22,815 | ||||||
| Other assets | 25,829 | 14,285 | ||||||
| Total Assets | $ | 387,207 | $ | 470,736 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Accounts payable, accrued expenses and other liabilities | $ | 56,324 | $ | 64,293 | ||||
| Deferred revenue | 82,319 | 74,045 | ||||||
| Operating lease liability | 23,154 | 29,574 | ||||||
| Debt | - | 4,061 | ||||||
| Deferred royalty obligation related to the sale of future royalties | 180,809 | 149,114 | ||||||
| Total liabilities | 342,606 | 321,087 | ||||||
| Total stockholders’ equity | 44,601 | 149,649 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 387,207 | $ | 470,736 |
| (1) | The condensed balance sheet as of December 31, 2024 was derived from the unaudited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 13, 2025. | |
| (2) | The condensed balance sheet as of December 31, 2023 was derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 25, 2024. |
FAQ**
What specific next-generation ADC programs has Sutro Biopharma Inc. (STRO) prioritized following the strategic portfolio review, and how will these choices impact future collaborations and revenue?
How do the recent management changes at Sutro Biopharma Inc. (STRO) align with the company's goals for its ADC pipeline and restructuring efforts moving forward?
With a cash position of $316.9 million and a runway extending to at least Q4 2026, how does Sutro Biopharma Inc. (STRO) plan to allocate its resources to optimize research and development while managing operating expenses?
During the conference call, what key updates should investors expect from Sutro Biopharma Inc. (STRO) regarding its financial outlook and anticipated milestones from existing collaborations?
**MWN-AI FAQ is based on asking OpenAI questions about Sutro Biopharma Inc. (NASDAQ: STRO).
NASDAQ: STRO
STRO Trading
1.35% G/L:
$40.11 Last:
145,027 Volume:
$43.85 Open:
